CEO of US Cancer Drug Developer Sells Shares Worth 240 Billion Won

On April 15, Mark A. Goldsmith, CEO of anti‐cancer drug developer Revolution Medicines, Inc. (Nasdaq: RVMD), exercised stock options to acquire 120,000 common shares and immediately sold them all on the open market at roughly $150 per share.

The sale was executed under a Rule 10b5-1 trading plan established in December 2024. In total, Goldsmith sold about $18 million of stock (approximately KRW 240 billion), reducing his direct holdings from around 397,000 shares to roughly 277,000 shares. He continues to hold several hundred thousand shares indirectly—via family trusts and approximately 200,000 restricted stock units (RSUs).

On April 13, Revolution Medicines announced that its lead candidate, daraxosilib, achieved statistically significant improvements in both overall survival (OS) and progression-free survival (PFS) versus standard chemotherapy in a Phase III trial in pancreatic cancer patients. Based on these results, the company plans to file for U.S. and other regulatory approvals by year-end.

In mid-April, the company also raised about $2.1 billion (roughly KRW 2.8 trillion) through a common stock offering and the issuance of 0.50% convertible notes. In a recent letter to competitor Erasca, Revolution Medicines alleged that Erasca’s pancreatic cancer candidate ERAS-0015 infringes its patents and misappropriates trade secrets, underscoring potential intellectual property disputes.

Headquartered in Redwood City, California, Revolution Medicines is a late-stage oncology biotech focused on cancers driven by RAS mutations. Built on its proprietary RAS(ON) inhibitor platform, the company’s pipeline includes daraxosilib and zolodrasilib. Founded in 2015 by Third Rock Ventures, Revolution Medicines has advanced rapidly toward commercialization.

Goldsmith is a physician-scientist who earned degrees from Princeton University and UCSF School of Medicine. He conducted research and clinical work at UCSF and the Gladstone Institutes before serving in leadership roles at Constellation Pharmaceuticals, Global Blood Therapeutics, Nurix Therapeutics and venture capital firm Third Rock Ventures.